Perceptive Advisors - Q4 2013 holdings

$833 Million is the total value of Perceptive Advisors's 118 reported holdings in Q4 2013. The portfolio turnover from Q3 2013 to Q4 2013 was 93.5% .

 Value Shares↓ Weighting
CELG SellCELGENE CORP$86,034,000
-23.5%
509,200
-30.2%
10.33%
+123.3%
ACRX SellACELRX PHARMACEUTICALS INC$74,353,000
-41.1%
6,574,060
-43.9%
8.93%
+71.7%
SRPT SellSAREPTA THERAPEUTICS INC$70,981,000
-68.7%
3,484,579
-84.9%
8.52%
-8.6%
VRTX SellVERTEX PHARMACEUTICALS INC$60,311,000
-12.0%
811,728
-10.2%
7.24%
+156.7%
TSRO SellTESARO INC$40,851,000
-65.2%
1,446,570
-52.2%
4.91%
+1.6%
NBIX SellNEUROCRINE BIOSCIENCES INC$39,076,000
-59.6%
4,183,737
-51.0%
4.69%
+17.9%
AEGR SellAEGERION PHARMACEUTICALS INC$31,775,000
-92.0%
447,785
-90.4%
3.82%
-76.8%
F113PS SellCOVIDIEN PLC$25,526,000
-0.9%
374,826
-11.3%
3.07%
+189.2%
EXAS SellEXACT SCIENCES CORP$23,031,000
-44.2%
1,969,903
-43.7%
2.77%
+62.8%
MNKD BuyMANNKIND CORP$19,772,000
+499.2%
3,795,000
+555.4%
2.38%
+1646.3%
MGNX NewMACROGENICS INC$19,687,000717,705
+100.0%
2.36%
WAG SellWALGREEN CO$18,496,000
-8.5%
322,000
-14.3%
2.22%
+166.9%
ABBV NewABBVIE INC$18,484,000350,000
+100.0%
2.22%
DYAX SellDYAX CORP$17,565,000
-24.4%
2,332,674
-31.1%
2.11%
+120.7%
NEPT SellNEPTUNE TECHNOLOGIES BIORESO$17,111,000
-50.0%
5,900,444
-45.2%
2.06%
+45.7%
MYL SellMYLAN INC$17,035,000
-51.5%
392,500
-57.4%
2.05%
+41.4%
XNCR NewXENCOR INC$14,338,0001,568,672
+100.0%
1.72%
INCY NewINCYTE CORP$13,609,000268,800
+100.0%
1.64%
SRPT NewSarepta Therapeutics Incput$13,241,000650,000
+100.0%
1.59%
BIIB NewBIOGEN IDEC INC$11,190,00040,000
+100.0%
1.34%
CI SellCIGNA CORPORATION$10,935,000
-68.1%
125,000
-72.0%
1.31%
-6.9%
SPNC BuySPECTRANETICS CORP$8,656,000
+67.2%
346,254
+12.4%
1.04%
+388.3%
RLYP NewRELYPSA INC$8,530,000341,200
+100.0%
1.02%
NewANACOR PHARMACEUTICALS INC$8,181,000487,542
+100.0%
0.98%
HNT SellHEALTH NET INC$8,094,000
-71.9%
272,775
-69.9%
0.97%
-17.9%
HTWR BuyHEARTWARE INTL INC$7,977,000
+989.8%
84,900
+749.0%
0.96%
+3093.3%
CHTP SellCHELSEA THERAPEUTICS INTL LT$7,538,000
-63.1%
1,701,639
-75.1%
0.90%
+7.6%
RTRX NewRETROPHIN INC$7,368,0001,052,692
+100.0%
0.88%
CTIC SellCELL THERAPEUTICS INC$7,133,000
-68.5%
3,715,000
-73.4%
0.86%
-8.2%
GENTY NewGENTIUM S P Asponsored adr$6,852,000120,000
+100.0%
0.82%
CVS BuyCVS CAREMARK CORPORATION$6,393,000
+2340.1%
89,330
+1842.0%
0.77%
+6881.8%
ZLTQ BuyZELTIQ AESTHETICS INC$5,779,000
+2230.2%
305,593
+1015.1%
0.69%
+6840.0%
ARNI NewARNO THERAPEUTICS$5,697,0002,034,721
+100.0%
0.68%
TARO NewTARO PHARMACEUTICAL INDS LTD$5,598,00056,602
+100.0%
0.67%
AERI NewAERIE PHARMACEUTICALS INC$5,388,000300,000
+100.0%
0.65%
ECYT SellENZO BIOCHEM INC$5,234,000
-53.1%
671,300
-19.8%
0.63%
+36.7%
ACST BuyACASTI PHARMA INC$5,236,000
+615.3%
4,389,685
+1321.7%
0.63%
+1996.7%
CSU SellCAPITAL SR LIVING CORP$5,008,000
-80.7%
208,753
-83.0%
0.60%
-43.8%
INFI SellINFINITY PHARMACEUTICALS INC$4,834,000
-29.0%
350,000
-10.3%
0.58%
+107.5%
ATHX SellATHERSYS INC$4,252,000
-39.7%
1,700,887
-60.4%
0.51%
+76.2%
ALQA NewALLIQUA$4,041,000557,491
+100.0%
0.48%
GILD SellGILEAD SCIENCES INC$3,758,000
-96.5%
50,000
-97.1%
0.45%
-89.9%
TNDM NewTANDEM DIABETES CARE INC$3,236,000125,600
+100.0%
0.39%
VSTM SellVERASTEM INC$2,517,000
-58.1%
220,000
-54.4%
0.30%
+22.3%
OPHT NewOPHTHOTECH CORP$2,426,00075,000
+100.0%
0.29%
MGCD SellMGC DIAGNOSTICS CORP$2,274,000
-40.5%
179,619
-48.5%
0.27%
+73.9%
CMRX NewCHIMERIX INC$2,262,000150,000
+100.0%
0.27%
RGEN BuyREPLIGEN CORPput$2,251,000
+48.7%
165,000
+20.8%
0.27%
+335.5%
ZGNX NewZOGENIX INC$2,236,000650,000
+100.0%
0.27%
FPRX NewFIVE PRIME THERAPEUTICS INC$2,225,000132,500
+100.0%
0.27%
ECYT NewENDOCYTE INCcall$2,138,000200,000
+100.0%
0.26%
ECYT SellENDOCYTE INCput$2,138,000
-58.5%
200,000
-48.2%
0.26%
+21.2%
AUXL NewAUXILIUM PHARMACEUTICALS INC$2,074,000100,000
+100.0%
0.25%
CSBR SellCHAMPION ONCOLOGY$1,950,000
-64.2%
1,625,744
-47.8%
0.23%
+4.5%
ZBH NewZIMMER HLDGS INC$1,864,00020,000
+100.0%
0.22%
CLVS SellCLOVIS ONCOLOGY INC$1,843,000
-92.2%
30,585
-92.1%
0.22%
-77.3%
IDIX NewIDENIX PHARMACEUTICALS INCcall$1,794,000300,000
+100.0%
0.22%
NBS SellNEOSTEM INC$1,566,000
-72.4%
229,593
-65.4%
0.19%
-19.3%
BCRX SellBIOCRYST PHARMACEUTICALS$1,501,000
-45.9%
197,500
-48.2%
0.18%
+57.9%
SNTS SellSANTARUS INC$1,451,000
-94.0%
45,400
-95.7%
0.17%
-82.4%
SHPG NewSHIRE PLCsponsored adr$1,413,00010,000
+100.0%
0.17%
ANTH SellANTHERA PHARMACEUTICALS INC$1,325,000
-61.8%
431,456
-50.0%
0.16%
+11.2%
RPRX SellREPROS THERAPEUTICS INC$1,315,000
-98.3%
71,879
-97.6%
0.16%
-95.2%
DXCM SellDEXCOM INC$1,062,000
-74.1%
30,000
-79.3%
0.13%
-24.3%
TBIO SellTRANSGENOMIC INC$1,004,000
-40.1%
2,207,500
-50.0%
0.12%
+75.4%
CRIS NewCURIS INC$987,000350,000
+100.0%
0.12%
VVUS SellVIVUS INCput$908,000
-83.1%
100,000
-82.7%
0.11%
-50.9%
ONTY SellONCOTHYREON INC$880,000
-55.7%
500,000
-48.2%
0.11%
+29.3%
MDXG NewMIMEDX GROUP INC$874,000100,000
+100.0%
0.10%
UPI SellUROPLASTY INC$857,000
-57.4%
313,989
-48.4%
0.10%
+24.1%
UTHR NewUNITED THERAPEUTICS CORP DEL$792,0007,000
+100.0%
0.10%
NewOREXIGEN THERAPEUTICS INCnote 2.750%12/0$732,000750,000
+100.0%
0.09%
SCAI NewSURGICAL CARE AFFILIATES INC$697,00020,000
+100.0%
0.08%
NSPH SellNANOSPHERE INC$676,000
-50.2%
295,000
-56.6%
0.08%
+44.6%
HOLX NewHOLOGIC INCcall$559,00025,000
+100.0%
0.07%
BLUE NewBLUEBIRD BIO INC$420,00020,000
+100.0%
0.05%
NCT NewNEWCASTLE INVT CORP$402,00070,000
+100.0%
0.05%
MDGN SellMEDGENICS INC$367,000
-84.3%
61,263
-79.6%
0.04%
-54.2%
ATHN NewATHENAHEALTH INCcall$336,0002,500
+100.0%
0.04%
STEM SellSTEMCELLS INC$334,000
-57.1%
271,600
-41.4%
0.04%
+25.0%
XNPT SellXENOPORT INC$288,000
-47.4%
50,000
-48.2%
0.04%
+52.2%
CUTR SellCUTERA INC$228,000
+3.6%
22,400
-9.7%
0.03%
+200.0%
INSYQ NewINSYS THERAPEUTICS INC NEW$221,0005,722
+100.0%
0.03%
ILMN NewILLUMINA INC$221,0002,000
+100.0%
0.03%
LCI NewLANNET INC$223,0006,744
+100.0%
0.03%
MDSO NewMEDIDATA SOLUTIONS INC$220,0003,642
+100.0%
0.03%
MYGN NewMYRIAD GENETICS INCput$210,00010,000
+100.0%
0.02%
NAVB SellNAVIDEA BIOPHARMACEUTICALS Iput$207,000
-66.5%
100,000
-57.1%
0.02%0.0%
TRNX NewTORNIER N V$188,00010,000
+100.0%
0.02%
PTIE NewPAIN THERAPEUTICS INC$172,00035,506
+100.0%
0.02%
DVA SellDAVITA HEALTHCARE PARTNERS I$151,000
-42.4%
2,382
-48.4%
0.02%
+63.6%
ESRX NewEXPRESS SCRIPTS HLDG CO$146,0002,080
+100.0%
0.02%
HRC NewHILL ROM HLDGS INC$152,0003,687
+100.0%
0.02%
NewANALOGIC CORP$146,0001,644
+100.0%
0.02%
CNC SellCENTENE CORP DEL$154,000
-49.0%
2,610
-44.6%
0.02%
+50.0%
NewASTRAZENECA PLCsponsored adr$152,0002,558
+100.0%
0.02%
IPXL NewIMPAX LABORATORIES INC$150,0005,962
+100.0%
0.02%
OCR SellOMNICARE INC$150,000
-46.4%
2,492
-50.7%
0.02%
+50.0%
ALR SellALERE INC$149,000
-44.8%
4,127
-53.4%
0.02%
+63.6%
RAD NewRITE AID CORP$76,00014,924
+100.0%
0.01%
FLDM NewFLUIDIGM CORP DEL$78,0002,030
+100.0%
0.01%
ENDP NewENDO HEALTH SOLUTIONS INC$77,0001,138
+100.0%
0.01%
PBYI NewPUMA BIOTECHNOLOGY INC$76,000735
+100.0%
0.01%
AFFX NewAFFYMETRIX INC$73,0008,538
+100.0%
0.01%
GERN NewGERON CORP$22,0004,684
+100.0%
0.00%
IMMU SellIMMUNOMEDICS INC$13,000
-99.9%
2,853
-99.8%
0.00%
-99.5%
AXGN SellAXOGEN INC$20,000
-50.0%
4,500
-50.0%
0.00%0.0%
CBMXW SellCOMBIMATRIX CORPORATION*w exp 05/01/201$3,000
-25.0%
5,000
-50.0%
0.00%
STML SellSTEMLINE THERAPEUTICS INC$1,000
-100.0%
38
-100.0%
0.00%
-100.0%
KYTH ExitKYTHERA BIOPHARMACEUTICALS I$0-5,530
-100.0%
-0.01%
HNGR ExitHANGER INC$0-8,160
-100.0%
-0.01%
AMSG ExitAMSURG CORP$0-6,830
-100.0%
-0.01%
MOH ExitMOLINA HEALTHCARE INC$0-7,180
-100.0%
-0.01%
AET ExitAETNA INC NEW$0-4,140
-100.0%
-0.01%
MGLN ExitMAGELLAN HEALTH SVCS INC$0-4,580
-100.0%
-0.01%
MD ExitMEDNAX INC$0-2,750
-100.0%
-0.01%
WOOF ExitVCA ANTECH INC$0-9,430
-100.0%
-0.01%
AZN ExitASTRAZENECA PLCsponsored adr$0-5,400
-100.0%
-0.01%
HLS ExitHEALTHSOUTH CORP$0-8,380
-100.0%
-0.01%
LPNT ExitLIFEPOINT HOSPITALS INC$0-5,990
-100.0%
-0.01%
CYH ExitCOMMUNITY HEALTH SYS INC NEW$0-6,830
-100.0%
-0.01%
FURX ExitFURIEX PHARMACEUTICALS INC$0-10,000
-100.0%
-0.02%
ASTX ExitASTEX PHARMACEUTICALS INC$0-94,196
-100.0%
-0.03%
VICL ExitVICAL INCcall$0-800,000
-100.0%
-0.04%
AVNR ExitAVANIR PHARMACEUTICALS INCput$0-386,000
-100.0%
-0.07%
PGNX ExitPROGENICS PHARMACEUTICALS IN$0-338,136
-100.0%
-0.07%
AMRN ExitAMARIN CORP PLCcall$0-289,600
-100.0%
-0.08%
VNDA ExitVANDA PHARMACEUTICALS INCput$0-193,000
-100.0%
-0.09%
TKMR ExitTEKMIRA PHARMACEUTICALS CORP$0-318,618
-100.0%
-0.09%
MYGN ExitMYRIAD GENETICS INCcall$0-116,600
-100.0%
-0.11%
CLDX ExitCELLDEX THERAPEUTICS INC NEWcall$0-96,600
-100.0%
-0.14%
KERX ExitKERYX BIOPHARMACEUTICALS INC$0-400,000
-100.0%
-0.17%
MDVN ExitMEDIVATION INC$0-96,500
-100.0%
-0.24%
MZOR ExitMAZOR ROBOTICS LTDsponsored ads$0-354,156
-100.0%
-0.25%
PSDV ExitPSIVIDA CORP$0-1,544,000
-100.0%
-0.26%
NBIX ExitNEUROCRINE BIOSCIENCES INCput$0-579,000
-100.0%
-0.27%
ANIK ExitANIKA THERAPEUTICS INC$0-288,134
-100.0%
-0.28%
CNDO ExitCORONADO BIOSCIENCES INCput$0-1,003,800
-100.0%
-0.29%
ARRY ExitARRAY BIOPHARMA INC$0-1,145,740
-100.0%
-0.29%
ITMN ExitINTERMUNE INC$0-600,000
-100.0%
-0.38%
RPRX ExitREPROS THERAPEUTICS INCcall$0-386,000
-100.0%
-0.43%
VNDA ExitVANDA PHARMACEUTICALS INCcall$0-965,200
-100.0%
-0.44%
AMRN ExitAMARIN CORP PLCput$0-1,737,000
-100.0%
-0.45%
ISIS ExitISIS PHARMACEUTICALS INC$0-385,600
-100.0%
-0.60%
WCG ExitWELLCARE HEALTH PLANS INC$0-264,162
-100.0%
-0.76%
VNDA ExitVANDA PHARMACEUTICALS INC$0-1,737,000
-100.0%
-0.78%
P103PS ExitNPS PHARMACEUTICALS INC$0-611,524
-100.0%
-0.80%
SGMO ExitSANGAMO BIOSCIENCES INC$0-1,930,000
-100.0%
-0.83%
AMGN ExitAMGEN INC$0-183,350
-100.0%
-0.84%
IWM ExitISHARESput$0-193,000
-100.0%
-0.85%
ANAC ExitANACOR PHARMACEUTICALS INC$0-1,947,736
-100.0%
-0.85%
PCRX ExitPACIRA PHARMACEUTICALS INC$0-544,068
-100.0%
-1.08%
ARNA ExitARENA PHARMACEUTICALS INCput$0-5,116,200
-100.0%
-1.11%
SNTA ExitSYNTA PHARMACEUTICALS CORP$0-4,762,472
-100.0%
-1.24%
ACAD ExitACADIA PHARMACEUTICALS INC$0-1,221,230
-100.0%
-1.38%
QCOR ExitQUESTCOR PHARMACEUTICALS INC$0-752,700
-100.0%
-1.80%
IBB ExitISHARESput$0-289,600
-100.0%
-2.50%
ONXX ExitONYX PHARMACEUTICALS INC$0-1,113,888
-100.0%
-5.72%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2014-02-14
Signatures

The EDGAR filing(s) were signed by:

About Perceptive Advisors

Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.

The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.

Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES SHARES42Q3 202315.7%
AMICUS THERAPEUTICS SHARES39Q3 202314.0%
ALDEYRA THERAPEUTICS SHARES35Q3 20233.3%
QUOTIENT TECHNOLOGY INC34Q3 20222.7%
GLOBAL BLOOD THERAPEUTICS SHARES29Q3 20229.3%
ADMA BIOLOGICS SHARES29Q3 20231.4%
RETROPHIN SHARES28Q3 20205.5%
DBV TECHNOLOGIES SA-SPON ADR28Q3 20211.8%
VBI VACCINES SHARES27Q1 20232.8%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%

View Perceptive Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Perceptive Advisors Q4 2013 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CHEMBIO DIAGNOSTICS, INC.Sold outMay 04, 202300.0%
VBI Vaccines Inc/BCApril 07, 202343,509,55316.7%
Landos Biopharma, Inc.March 30, 202314,869,91547.7%
REATA PHARMACEUTICALS INCMarch 07, 20232,083,7996.5%
AGILE THERAPEUTICS INCSold outFebruary 14, 202300.0%
ALBIREO PHARMA, INC.February 14, 20231,757,1608.5%
BELLUS Health Inc.February 14, 20238,891,0277.1%
CinCor Pharma, Inc.February 14, 20232,576,3255.9%
Coherus BioSciences, Inc.Sold outFebruary 14, 202300.0%
CONCERT PHARMACEUTICALS, INC.February 14, 20231,800,0003.6%

View Perceptive Advisors's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D2024-03-20
SC 13G2024-03-14
SC 13G2024-03-11
SC 13G/A2024-03-06
SC 13D/A2024-03-01
SC 13G2024-03-01
SC 13D/A2024-02-29
13F-HR/A2024-02-26
SC 13G/A2024-02-23
42024-02-21

View Perceptive Advisors's complete filings history.

Compare quarters

Export Perceptive Advisors's holdings